Oral MS treatments to dominate the market by 2014 as U.S and European approvals approach
Russia’s approval this week of Merck Serono’s Movectro (oral cladribine) marks a major shift towards new oral treatments for multiple sclerosis (MS), according to industry analysts Datamonitor.
Datamonitor tips Swiss firm to reach CAGR of four percent to 2015
Swiss-based
Novartis is expected to be the world’s best performing pharmaceutical company over the next five years, bolstered by its vaccine and generics businesses.
Novartis Australia has received Therapeutic Goods Administration approval for Afinitor.
Novartis Australia has received Therapeutic Goods Administration approval for Afinitor.
